Market Overview
The tumor ablation market is a rapidly growing market that is expected to reach a value of $4.07 billion by 2030. Tumor ablation is a minimally invasive procedure that uses heat, cold, or other energy to destroy cancer cells. It is a less invasive alternative to surgery and can be used to treat tumors in a variety of locations, including the liver, kidney, lung, and prostate.
Key Players
The tumor ablation market players include:
- Medtronic Plc
- Boston Scientific Corporation
- AngioDynamics Inc.
- Abbott
- Merit Medical Systems
- Galil Medical, Inc.
- EDAP TMS SA
- Hologic Inc.
- SonaCare Technologies, Inc.
- AtriCure, Inc.
These companies offer a variety of tumor ablation devices and technologies.
There are a number of factors driving the growth of the tumor ablation market, including:
- Rising prevalence of cancer: The global cancer incidence is expected to reach 23.6 million cases by 2030. This increase in cancer cases is driving the demand for minimally invasive treatment options such as tumor ablation.
- Improvements in technology: Technological advancements in tumor ablation devices are making the procedures more effective and safer. For example, new ultrasound-guided tumor ablation devices allow doctors to precisely target tumors with heat energy.
- Preference for minimally invasive procedures: Patients are increasingly preferring minimally invasive procedures over surgery due to the shorter recovery time and lower risk of complications.
- Cost-effectiveness: Tumor ablation is a cost-effective treatment option for many patients, especially those who are not good candidates for surgery.
The tumor ablation market is segmented by technology, treatment, application, and region. The technology segment is further segmented into radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, irreversible electroporation ablation (IRE), and others. The treatment segment is further segmented into surgical ablation, laparoscopic ablation, and percutaneous ablation. The application segment is further segmented into kidney cancer, liver cancer, breast cancer, lung cancer, and prostate cancer. The region segment is further segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America is the largest market for tumor ablation, followed by Europe and Asia Pacific. This is due to the high prevalence of cancer and the availability of advanced technology in these regions. The Asia Pacific region is expected to grow at the fastest CAGR during the forecast period, due to the increasing incidence of cancer and the growing demand for minimally invasive procedures in this regions
About US:
Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Service
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
No comments:
Post a Comment